Naghavi-Behzad, M.; Oltmann, H.R.; Alamdari, T.A.; Bülow, J.L.; Ljungstrøm, L.; Braad, P.-E.; Asmussen, J.T.; Vogsen, M.; Kodahl, A.R.; Gerke, O.;
et al. Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. Cancers 2021, 13, 4080.
https://doi.org/10.3390/cancers13164080
AMA Style
Naghavi-Behzad M, Oltmann HR, Alamdari TA, Bülow JL, Ljungstrøm L, Braad P-E, Asmussen JT, Vogsen M, Kodahl AR, Gerke O,
et al. Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. Cancers. 2021; 13(16):4080.
https://doi.org/10.3390/cancers13164080
Chicago/Turabian Style
Naghavi-Behzad, Mohammad, Hjalte Rasmus Oltmann, Tural Asgharzadeh Alamdari, Jakob Lykke Bülow, Lasse Ljungstrøm, Poul-Erik Braad, Jon Thor Asmussen, Marianne Vogsen, Annette Raskov Kodahl, Oke Gerke,
and et al. 2021. "Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer" Cancers 13, no. 16: 4080.
https://doi.org/10.3390/cancers13164080
APA Style
Naghavi-Behzad, M., Oltmann, H. R., Alamdari, T. A., Bülow, J. L., Ljungstrøm, L., Braad, P.-E., Asmussen, J. T., Vogsen, M., Kodahl, A. R., Gerke, O., & Hildebrandt, M. G.
(2021). Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. Cancers, 13(16), 4080.
https://doi.org/10.3390/cancers13164080